Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECF versus ECX for advanced gastric cancer
ISRCTN72792659Phase 2Completed
- Sponsor
- Ministry of Higher Education, Science and Technology
- Start
- Jan 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin, cisplatin, fluorouracil and capecitabine in gastric cancer (GC) (2 arms), sponsored by Ministry of Higher Education, Science and Technology. Primary endpoint: Response rate. Started Jan 2003; status: completed.
02
Drugs
epirubicincisplatinfluorouracilcapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ISRCTN72792659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72792659.